Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
The target population typically has better health than participants in health research studies, such as cancer screening trials (the "healthy volunteer" effect).
Read Full NewsHigher vs lower nighttime light exposure is associated with increased risk for obesity, hypertension, and dyslipidemia in patients with schizophrenia, a study suggests.
Transperineal 3D mapping biopsy may help select patients with low-risk prostate cancer who are most likely to fare well with active surveillance.
Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.
1.
Trump slashed US cancer research by 31 percent: Senate report
2.
PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.
3.
A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.
4.
FDA approves rivanetin as the first-line treatment for lung cancer.
5.
Black women are more likely to die of breast cancer. Close the gap by looking into mammogram studies.
1.
Progressive Strategies in Oncology and Patient Outcomes
2.
Virtual Oncology Care Continuums: Transforming Cancer Management Through Digital Innovation
3.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
4.
Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging
5.
Bone Marrow Regenerative Capacity and Hematologic Recovery
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part V
2.
Navigating the Complexities of Ph Negative ALL - Part VIII
3.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
5.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge